Last reviewed · How we verify

NCT05372055: MY-IPC

Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients

Completed Last updated 9 June 2023
What this trial tests

trial testing Semi-structure interviews in Malignant Pleural Effusion in 18 participants. Completed in 8 May 2023.

Timeline
9 May 2022
Primary endpoint
8 May 2023
8 May 2023

Quick facts

Lead sponsorGuy's and St Thomas' NHS Foundation Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment18
Start date9 May 2022
Primary completion8 May 2023
Estimated completion8 May 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Guy's and St Thomas' NHS Foundation Trust

Who can join

18 and older, any sex, with Malignant Pleural Effusion or Indwelling Pleural Catheter. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to better understand the impact that Indwelling Pleural Catheters have on patients with malignant pleural effusions from a psychosocial point of view.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Psychosocial impact of living with an indwelling pleural catheter in patients with malignant pleural effusions: a thematic analysis.
    Zhang J, Liang J, Agoramoorthy L, Montalvo S, et al · · 2025 · cited 1× · PMID 40628689 · DOI 10.1136/bmjresp-2024-002993

Verify or expand the search:

Other trials of Semi-structure interviews

Trials testing the same drug.

Other recruiting trials for Malignant Pleural Effusion

Currently open trials in the same condition.

Other Guy's and St Thomas' NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05372055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing